BioMérieux: up after positive analysis

(CercleFinance.com) - The stock is up nearly +2%, benefiting from the positive analysis of Invest Securities

While raising its price target from 130 to 133 euros, Invest Securities reiterates its 'buy' opinion on bioMérieux, a stock which it "feels is insufficiently valued in relation to its peers, given its market positioning and risk profile".


"On Friday, the group announced 2024 results that exceeded expectations and exceeded targets. For 2025, targets are in line with the GO-28 plan and broadly in line with our expectations", the analyst points out.

Particularly satisfied with the momentum of the four growth pillars, which are evolving at the top end of the GO-28 plan targets, the analyst believes that these levers are establishing bioMérieux as "a true growth champion in the IVD market".

Copyright (c) 2025 CercleFinance.com. All rights reserved.